Fortrea Holdings Inc. (FTRE)

In March 2025, the stock declined after disappointing Q4 and full-year 2024 financial results. In July 2025, a securities class action lawsuit was filed against Fortrea alleging investors were misled about the company's finances post-spin-off. In August 2025, Fortrea announced employment inducement awards for its new President and CEO. In September 2024, a report led to a decline in Fortrea's stock price. In October 2025, the stock jumped after Fortrea announced a cash tender offer to repurchase its senior secured notes due 2030. Analyst ratings have been mixed, with a consensus rating of "Hold" and an average price target of $12.39 as of late October 2025.

There is no explicit information indicating significant demand seasonality for Fortrea Holdings, Inc.'s products and services. The CRO services market is projected to grow steadily, driven by increasing outsourcing and the rising complexity of drug development. However, market-driven fluctuations in biotech funding and research initiatives can influence demand for CRO services.

Fortrea Holdings, Inc. is a global contract research organization (CRO) providing clinical development solutions to the life sciences industry. It spun off from Labcorp in July 2023 and operates in the Healthcare sector, specifically within the Biotechnology and Medical Research industry. Fortrea offers biopharmaceutical product and medical device development services, including Phase I-IV clinical trial management, clinical pharmacology, and consulting services. The company provides flexible delivery models and patient access and clinical trial technology solutions.

Fortrea Holdings, Inc. has a global presence with primary office locations in the United States, the United Kingdom, China, India, and Singapore. The company also has field operations in over 90 countries.

Fortrea's brand reputation has been impacted by a securities class action lawsuit filed in July 2025, alleging that the company and its executives misled investors regarding its financial outlook post-spin-off from Labcorp. This legal action and the associated allegations of misrepresentation could negatively affect the company's standing among investors and potentially clients.

Fortrea Holdings Inc. has significant institutional ownership, with 621 institutional owners and shareholders holding a total of 117,583,815 shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and Goldman Sachs Group Inc. Individual insider trading activity in the past quarter includes purchases by Director Peter M. Neupert and Director Erin L. Russell, and a sale by CFO Jill G. Mcconnell.